Drug Profile
BW 1010
Alternative Names: BW-1010; rPA/NE01 anthrax vaccineLatest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator NanoBio Corporation; Public Health England
- Developer BlueWillow Biologics; Porton Biopharma
- Class Anthrax vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Anthrax
Most Recent Events
- 28 Dec 2022 Phase I development in Anthrax (Prevention) is ongoing in USA (Intranasal) (BlueWillow Biologics pipeline, December 2022)
- 26 Oct 2021 BlueWillow Biologics plans a late-stage clinical trials for Anthrax (Prevention) (Intranasal) as early as 2023
- 30 Sep 2021 BlueWillow Biologics completes a phase I trial in Anthrax (Prevention) in the USA (Intranasal) (NCT04148118)